Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANGIO-A: Atezolizumab, Bevacizumab, Sorafenib, and Cyclophosphamide in Pediatric Solid Tumors
NCT05468359Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2022
- Primary completion
- Jun 2032
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in solid tumor, fibrolamellar carcinoma (FLC), hepatocellular carcinoma (HCC), desmoplastic small round cell tumor (DSRCT), malignant rhabdoid tumor (MRT), sponsored by St. Jude Children's Research Hospital. Started Nov 2022; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
solid tumorfibrolamellar carcinoma (FLC)hepatocellular carcinoma (HCC)desmoplastic small round cell tumor (DSRCT)malignant rhabdoid tumor (MRT)
Beyond the preview
Go deeper on NCT05468359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468359.